This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Rutgers, The State University of New Jersey. Active years: 2021-2024.
Company Filing History:
Years Active: 2021-2024
Title: Glenn Capodagli: Innovator in Therapeutic Indazoles
Introduction
Glenn Capodagli is a notable inventor based in New Brunswick, NJ (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic compounds. With a total of 2 patents, his work focuses on addressing critical health issues, such as bacterial infections.
Latest Patents
Capodagli's latest patents include innovative compounds known as therapeutic indazoles. These compounds are described by a specific formula and are designed to treat bacterial infections, including tuberculosis. The invention provides compounds of formula I and salts thereof, wherein R-R have various meanings as detailed in the specification. This advancement holds promise for improving treatment options for serious infections.
Career Highlights
Glenn Capodagli is affiliated with Rutgers, the State University of New Jersey, where he continues to engage in research and development. His work has been instrumental in advancing the understanding and treatment of bacterial infections through innovative chemical compounds.
Collaborations
Capodagli has collaborated with esteemed colleagues, including Joel S. Freundlich and David Alland. These partnerships have fostered a collaborative environment that enhances the research and development of therapeutic solutions.
Conclusion
In summary, Glenn Capodagli is a dedicated inventor whose work in therapeutic indazoles contributes significantly to the fight against bacterial infections. His innovative approach and collaborations with fellow researchers underscore his commitment to advancing medical science.